All very quiet with ave. Quiet before the storm?
phase 3 soft gel insomnia ethics approval expected before years end. Dosing first quarter of 2023.
channel 9 had a report on a cbd trial for insomnia. Don't think it was ave but it looked very similar. Shame we may have missed first mover status...
lambert institute-using cbg phase 2 trial should have results end of q1 2023
canine study - report on absorption rates with food... should be results very soon
perland - phase 1 b osteoarthritis study - q1 2023...
and the mysterious unknown indication trial by my research it is in the dermatology space...
unfortunately the lack of news around team saas suggests it's hit some sort of road block and knowing aves history it's a safe bet that it won't progress
Critical six months
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $9.508M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $616 | 184.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 47 | 99114058 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 34826820 | 25 |
View Market Depth
| Last trade - 16.10pm 14/06/2024 (20 minute delay) ? |
|
|||||
|
Last
0.3¢ |
Change
-0.001 ( 14.3 %) |
||||
| Open | High | Low | Volume | ||
| 0.3¢ | 0.3¢ | 0.3¢ | 14964 | ||
| Last updated 15.57pm 14/06/2024 ? | |||||
| AVE (ASX) Chart |